Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 18,750 Shares

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $27,079,091.58. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

William Lewis also recently made the following trade(s):

• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Trading Down 3.0 %

Shares of INSM stock opened at $81.06 on Friday. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock’s 50 day simple moving average is $74.29 and its two-hundred day simple moving average is $73.59. The company has a market cap of $14.50 billion, a PE ratio of -14.50 and a beta of 1.11.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INSM has been the topic of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Wednesday. JPMorgan Chase & Co. boosted their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday. Stifel Nicolaus decreased their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Morgan Stanley boosted their target price on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of INSM. Exchange Traded Concepts LLC grew its stake in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 627 shares during the last quarter. Creative Planning grew its stake in shares of Insmed by 31.2% during the third quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company’s stock valued at $3,279,000 after buying an additional 10,668 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Insmed by 2,348.8% during the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 1,879 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Insmed by 18.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 390,134 shares of the biopharmaceutical company’s stock valued at $28,480,000 after buying an additional 62,061 shares during the last quarter. Finally, JCIC Asset Management Inc. bought a new position in shares of Insmed during the third quarter valued at approximately $133,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.